Examining Real-World Attrition Among Patients Undergoing Complement Inhibitor Intravitreal Therapy for Geographic Atrophy
- 29 July 2026
- journal article
- research article
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
Abstract
Purpose: To identify characteristics of patients with geographic atrophy (GA) who received pegcetacoplan or avacincaptad pegol and discontinued treatment. Methods: Two complementary retrospective cohort studies of a large, geographically and demographically diverse, deidentified database were performed. One analysis assessed baseline characteristics. Eyes with 12 months of data were included in a subsequent analysis of follow-up changes/characteristics. Univariate and multivariate mixed-effects Cox proportional hazard and logistic regression models, respectively, were used to estimate the hazard ratio (HR) and odds ratio (OR) of attrition. Results: A total of 21 914 eyes were identified for the baseline analysis, 14 690 (67%) of which received pegcetacoplan and 7224 (33%) avacincaptad pegol. Mean (±SD) patient age was 82.1 ± 7.85 years. Treatment retention declined between 0 and 12 months. Baseline predictors of attrition were age older than 90 years (HR, 1.26; 95% CI, 1.03-1.55; P = .028), pegcetacoplan treatment (HR, 3.32; 95% CI, 2.92-3.76; P < .001), treated (HR, 1.56; 95% CI, 1.40-1.75; P < .001) and untreated (HR, 1.41; 95% CI, 1.21-1.64; P < .001) neovascular age-related macular degeneration (nAMD), visual acuity of less than 35 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (HR, 1.45; 95% CI, 1.25-1.67; P < .001), and subfoveal GA (HR, 1.15; 95% CI, 1.04-1.27; P = .007). Poor baseline visual acuity remained significant in the adjusted 12-month analysis. Significant predictors included new nAMD (OR, 3.02; 95% CI, 2.35-3.89; P < .001) and a loss of more than 5 ETDRS letters (OR, 1.36; 95% CI, 1.17-1.58; P < .001). nAMD treatment intervals of more than 6 weeks (OR, 0.59; 95% CI, 0.39-0.90; P = .014) and GA treatment intervals of 6 to 8 weeks (OR, 0.56; 95% CI, 0.43-0.74; P < .001) contributed to decreased odds of attrition. Conclusions: Poor baseline vision and development of new nAMD are associated with patient attrition, and the combination of nAMD and GA and treatment burden challenges patient retention.Keywords
This publication has 41 references indexed in Scilit:
- Erratum to “Visual Function Benefit After Treatment With Pegcetacoplan: Microperimetry Analysis From the Phase 3 OAKS Trial,” [Am J Ophthalmol 2025; 273:119-129]American Journal of Ophthalmology, 2025
- National survey of financial burden and experience among patients with cancer and autoimmune disease receiving charitable copay assistanceCancer, 2025
- Age-Related Macular DegenerationJAMA, 2024
- Enlargement of Geographic Atrophy From First Diagnosis to End of LifeJAMA Ophthalmology, 2021
- Demographic and Clinical Factors that Influence the Visual Response to Anti-Vascular Endothelial Growth Factor Therapy in Patients with Neovascular Age-Related Macular Degeneration: A Systematic ReviewOphthalmology and Therapy, 2020
- Disease Burden in the Treatment of Age-Related Macular Degeneration: Findings From a Time-and-Motion StudyAmerican Journal of Ophthalmology, 2015
- Treatment Patterns for Neovascular Age-Related Macular Degeneration: Analysis of 284 380 Medicare BeneficiariesAmerican Journal of Ophthalmology, 2012
- Change in Area of Geographic Atrophy in the Age-Related Eye Disease StudyArchives of Ophthalmology (1950), 2009
- The Epidemiology of Progression of Pure Geographic Atrophy: The Beaver Dam Eye StudyAmerican Journal of Ophthalmology, 2008
- Changes in Visual Acuity in a Population Over a 15-year Period: The Beaver Dam Eye StudyAmerican Journal of Ophthalmology, 2006